Modulation of ischaemic contracture in mouse hearts: A 'supraphysiological' response to adenosine

Melissa E. Reichelt, Laura Willems, Jason N. Peart, Kevin J. Ashton, G. Paul Matherne, Michael R. Blackburn, John P. Headrick

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

While inhibition of ischaemic contracture was one of the first documented cardioprotective actions of exogenously applied adenosine, it is not known whether this is a normal function of endogenous adenosine generated during ischaemic stress. Additionally, the relevance of delayed contracture to postischaemic outcome is unclear. We tested the ability of endogenous versus exogenous adenosine to modify contracture (and postischaemic outcomes) in C57/Bl6 mouse hearts. During ischaemia, untreated hearts developed peak contracture (PC) of 85 ± 5 mmHg at 8.9 ± 0.8 min, with time to reach 20 mmHg (time to onset of contracture; TOC) of 4.4 ± 0.3 min. Adenosine (50 μm) delayed TOC to 6.7 ± 0.6 min, as did pretreatment with 10 μm 2-chloroadenosine (7.2 ± 0.5 min) or 50 nm of A1 adenosine receptor (AR) agonist N6-cyclohexyladenosine (CHA) (6.7 ± 0.3 min), but not A2AAR or A3AR agonists (20 nm 2-[4-(2-carboxyethyl) phenethylamino]-5′ N-methylcarboxamidoadenosine (CGS21680) or 150 nm 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N- methyluronamide (Cl-IB-MECA), respectively). Adenosinergic contracture inhibition was eliminated by A1AR gene knockout (KO), mimicked by A1AR overexpression, and was associated with preservation of myocardial [ATP]. This adenosine-mediated inhibition of contracture was, however, only evident after prolonged (10 or 15 min) and not brief (3 min) pretreatment. Ischaemic contracture was also insensitive to endogenously generated adenosine, since A1AR KO, and non-selective and A 1AR-selective antagonists (50 μm 8-sulphophenyltheophylline and 150 nm 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX), respectively), all failed to alter intrinsic contracture development. Finally, delayed contracture with A1AR agonism/overexpression or ischaemic 2,3-butanedione monoxime (BDM; 5 μm to target Ca2+ cross-bridge formation) was linked to enhanced postischaemic outcomes. In summary, adenosinergic inhibition of contracture is solely A1AR mediated; the response is 'supraphysiological', evident only with significant periods of pre-ischaemic AR agonism (or increased A1AR density); and ischaemic contracture appears insensitive to locally generated adenosine, potentially owing to the rapidity of contracture development versus the finite time necessary for expression of AR-mediated cardioprotection.

Original languageEnglish
Pages (from-to)175-185
Number of pages11
JournalExperimental Physiology
Volume92
Issue number1
DOIs
Publication statusPublished - Jan 2007
Externally publishedYes

Fingerprint

Ischemic Contracture
Contracture
Adenosine
Purinergic P1 Receptors
Adenosine A1 Receptor Agonists
2-Chloroadenosine
Gene Knockout Techniques
Ischemia
Adenosine Triphosphate

Cite this

Reichelt, M. E., Willems, L., Peart, J. N., Ashton, K. J., Matherne, G. P., Blackburn, M. R., & Headrick, J. P. (2007). Modulation of ischaemic contracture in mouse hearts: A 'supraphysiological' response to adenosine. Experimental Physiology, 92(1), 175-185. https://doi.org/10.1113/expphysiol.2006.035568
Reichelt, Melissa E. ; Willems, Laura ; Peart, Jason N. ; Ashton, Kevin J. ; Matherne, G. Paul ; Blackburn, Michael R. ; Headrick, John P. / Modulation of ischaemic contracture in mouse hearts : A 'supraphysiological' response to adenosine. In: Experimental Physiology. 2007 ; Vol. 92, No. 1. pp. 175-185.
@article{ed5f088a206844b4aa6ce22b8c8da5c1,
title = "Modulation of ischaemic contracture in mouse hearts: A 'supraphysiological' response to adenosine",
abstract = "While inhibition of ischaemic contracture was one of the first documented cardioprotective actions of exogenously applied adenosine, it is not known whether this is a normal function of endogenous adenosine generated during ischaemic stress. Additionally, the relevance of delayed contracture to postischaemic outcome is unclear. We tested the ability of endogenous versus exogenous adenosine to modify contracture (and postischaemic outcomes) in C57/Bl6 mouse hearts. During ischaemia, untreated hearts developed peak contracture (PC) of 85 ± 5 mmHg at 8.9 ± 0.8 min, with time to reach 20 mmHg (time to onset of contracture; TOC) of 4.4 ± 0.3 min. Adenosine (50 μm) delayed TOC to 6.7 ± 0.6 min, as did pretreatment with 10 μm 2-chloroadenosine (7.2 ± 0.5 min) or 50 nm of A1 adenosine receptor (AR) agonist N6-cyclohexyladenosine (CHA) (6.7 ± 0.3 min), but not A2AAR or A3AR agonists (20 nm 2-[4-(2-carboxyethyl) phenethylamino]-5′ N-methylcarboxamidoadenosine (CGS21680) or 150 nm 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N- methyluronamide (Cl-IB-MECA), respectively). Adenosinergic contracture inhibition was eliminated by A1AR gene knockout (KO), mimicked by A1AR overexpression, and was associated with preservation of myocardial [ATP]. This adenosine-mediated inhibition of contracture was, however, only evident after prolonged (10 or 15 min) and not brief (3 min) pretreatment. Ischaemic contracture was also insensitive to endogenously generated adenosine, since A1AR KO, and non-selective and A 1AR-selective antagonists (50 μm 8-sulphophenyltheophylline and 150 nm 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX), respectively), all failed to alter intrinsic contracture development. Finally, delayed contracture with A1AR agonism/overexpression or ischaemic 2,3-butanedione monoxime (BDM; 5 μm to target Ca2+ cross-bridge formation) was linked to enhanced postischaemic outcomes. In summary, adenosinergic inhibition of contracture is solely A1AR mediated; the response is 'supraphysiological', evident only with significant periods of pre-ischaemic AR agonism (or increased A1AR density); and ischaemic contracture appears insensitive to locally generated adenosine, potentially owing to the rapidity of contracture development versus the finite time necessary for expression of AR-mediated cardioprotection.",
author = "Reichelt, {Melissa E.} and Laura Willems and Peart, {Jason N.} and Ashton, {Kevin J.} and Matherne, {G. Paul} and Blackburn, {Michael R.} and Headrick, {John P.}",
year = "2007",
month = "1",
doi = "10.1113/expphysiol.2006.035568",
language = "English",
volume = "92",
pages = "175--185",
journal = "Quarterly Journal of Experimental Physiology",
issn = "0958-0670",
publisher = "Wiley-Blackwell",
number = "1",

}

Reichelt, ME, Willems, L, Peart, JN, Ashton, KJ, Matherne, GP, Blackburn, MR & Headrick, JP 2007, 'Modulation of ischaemic contracture in mouse hearts: A 'supraphysiological' response to adenosine' Experimental Physiology, vol. 92, no. 1, pp. 175-185. https://doi.org/10.1113/expphysiol.2006.035568

Modulation of ischaemic contracture in mouse hearts : A 'supraphysiological' response to adenosine. / Reichelt, Melissa E.; Willems, Laura; Peart, Jason N.; Ashton, Kevin J.; Matherne, G. Paul; Blackburn, Michael R.; Headrick, John P.

In: Experimental Physiology, Vol. 92, No. 1, 01.2007, p. 175-185.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Modulation of ischaemic contracture in mouse hearts

T2 - A 'supraphysiological' response to adenosine

AU - Reichelt, Melissa E.

AU - Willems, Laura

AU - Peart, Jason N.

AU - Ashton, Kevin J.

AU - Matherne, G. Paul

AU - Blackburn, Michael R.

AU - Headrick, John P.

PY - 2007/1

Y1 - 2007/1

N2 - While inhibition of ischaemic contracture was one of the first documented cardioprotective actions of exogenously applied adenosine, it is not known whether this is a normal function of endogenous adenosine generated during ischaemic stress. Additionally, the relevance of delayed contracture to postischaemic outcome is unclear. We tested the ability of endogenous versus exogenous adenosine to modify contracture (and postischaemic outcomes) in C57/Bl6 mouse hearts. During ischaemia, untreated hearts developed peak contracture (PC) of 85 ± 5 mmHg at 8.9 ± 0.8 min, with time to reach 20 mmHg (time to onset of contracture; TOC) of 4.4 ± 0.3 min. Adenosine (50 μm) delayed TOC to 6.7 ± 0.6 min, as did pretreatment with 10 μm 2-chloroadenosine (7.2 ± 0.5 min) or 50 nm of A1 adenosine receptor (AR) agonist N6-cyclohexyladenosine (CHA) (6.7 ± 0.3 min), but not A2AAR or A3AR agonists (20 nm 2-[4-(2-carboxyethyl) phenethylamino]-5′ N-methylcarboxamidoadenosine (CGS21680) or 150 nm 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N- methyluronamide (Cl-IB-MECA), respectively). Adenosinergic contracture inhibition was eliminated by A1AR gene knockout (KO), mimicked by A1AR overexpression, and was associated with preservation of myocardial [ATP]. This adenosine-mediated inhibition of contracture was, however, only evident after prolonged (10 or 15 min) and not brief (3 min) pretreatment. Ischaemic contracture was also insensitive to endogenously generated adenosine, since A1AR KO, and non-selective and A 1AR-selective antagonists (50 μm 8-sulphophenyltheophylline and 150 nm 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX), respectively), all failed to alter intrinsic contracture development. Finally, delayed contracture with A1AR agonism/overexpression or ischaemic 2,3-butanedione monoxime (BDM; 5 μm to target Ca2+ cross-bridge formation) was linked to enhanced postischaemic outcomes. In summary, adenosinergic inhibition of contracture is solely A1AR mediated; the response is 'supraphysiological', evident only with significant periods of pre-ischaemic AR agonism (or increased A1AR density); and ischaemic contracture appears insensitive to locally generated adenosine, potentially owing to the rapidity of contracture development versus the finite time necessary for expression of AR-mediated cardioprotection.

AB - While inhibition of ischaemic contracture was one of the first documented cardioprotective actions of exogenously applied adenosine, it is not known whether this is a normal function of endogenous adenosine generated during ischaemic stress. Additionally, the relevance of delayed contracture to postischaemic outcome is unclear. We tested the ability of endogenous versus exogenous adenosine to modify contracture (and postischaemic outcomes) in C57/Bl6 mouse hearts. During ischaemia, untreated hearts developed peak contracture (PC) of 85 ± 5 mmHg at 8.9 ± 0.8 min, with time to reach 20 mmHg (time to onset of contracture; TOC) of 4.4 ± 0.3 min. Adenosine (50 μm) delayed TOC to 6.7 ± 0.6 min, as did pretreatment with 10 μm 2-chloroadenosine (7.2 ± 0.5 min) or 50 nm of A1 adenosine receptor (AR) agonist N6-cyclohexyladenosine (CHA) (6.7 ± 0.3 min), but not A2AAR or A3AR agonists (20 nm 2-[4-(2-carboxyethyl) phenethylamino]-5′ N-methylcarboxamidoadenosine (CGS21680) or 150 nm 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N- methyluronamide (Cl-IB-MECA), respectively). Adenosinergic contracture inhibition was eliminated by A1AR gene knockout (KO), mimicked by A1AR overexpression, and was associated with preservation of myocardial [ATP]. This adenosine-mediated inhibition of contracture was, however, only evident after prolonged (10 or 15 min) and not brief (3 min) pretreatment. Ischaemic contracture was also insensitive to endogenously generated adenosine, since A1AR KO, and non-selective and A 1AR-selective antagonists (50 μm 8-sulphophenyltheophylline and 150 nm 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX), respectively), all failed to alter intrinsic contracture development. Finally, delayed contracture with A1AR agonism/overexpression or ischaemic 2,3-butanedione monoxime (BDM; 5 μm to target Ca2+ cross-bridge formation) was linked to enhanced postischaemic outcomes. In summary, adenosinergic inhibition of contracture is solely A1AR mediated; the response is 'supraphysiological', evident only with significant periods of pre-ischaemic AR agonism (or increased A1AR density); and ischaemic contracture appears insensitive to locally generated adenosine, potentially owing to the rapidity of contracture development versus the finite time necessary for expression of AR-mediated cardioprotection.

UR - http://www.scopus.com/inward/record.url?scp=33846228335&partnerID=8YFLogxK

U2 - 10.1113/expphysiol.2006.035568

DO - 10.1113/expphysiol.2006.035568

M3 - Article

VL - 92

SP - 175

EP - 185

JO - Quarterly Journal of Experimental Physiology

JF - Quarterly Journal of Experimental Physiology

SN - 0958-0670

IS - 1

ER -